Patients with ADPKD and ARPKD are diagnosed according to the Japanese PKD guideline criteria, or genetic information. For the ADPKD cohort, patients with an eGFR more than 15.0 will be included.
Exclusion criteria include: history of kidney transplantation, active cancer, cancer treatment within last 5 years, or participation in a PKD-related clinical trial. If pathological or genetic examinations reveal that a patient has a type of PKD other than ADPKD or ARPKD, they will be excluded from the study, even if they have already enrolled.
年齢下限 / Age Minimum
下限なし
No limit
年齢上限 / Age Maximum
上限なし
No limit
性別 / Gender
中止基準
① 研究対象者から研究参加の辞退の申し出や同意の撤回があった場合 ② 本研究全体が中止された場合 ③ その他の理由により,研究責任者および研究分担者が研究の中止が適当と判断した場合
The primary end point from the JRP is kidney composite events, including kidney replacement therapy (hemodialysis, peritoneal dialysis and kidney transplantation), and a 50% decline in eGFR.
副次的な評価項目 / Secondary Outcome(s)
ADPKD: 腎容積増増大速度 、死亡、 入院、患者アンケート
ARPKD: 腎予後 、肝予後
Subsequent end points for patients with ADPKD include: annual rate of change in TKV, annual rate of change in eGFR, PROs, hospitalization, infection, CVD events, and all-cause mortality.
Subsequent end points for patients with ARPKD patients include: liver transplantation, all-cause mortality, intellectual disability, and schooling and employment status.